NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD
3.13
-0.09 (-2.8%)
The current stock price of ABSI is 3.13 USD. In the past month the price increased by 11.39%. In the past year, price decreased by -31.66%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
NTRA | NATERA INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. The firm combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. The company is developing a diversified portfolio of programs with a focus on cytokine biology. The company has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 155
Company Website: https://www.absci.com/
Investor Relations: https://investors.absci.com/
Phone: 13609491041
The current stock price of ABSI is 3.13 USD. The price decreased by -2.8% in the last trading session.
The exchange symbol of ABSCI CORP is ABSI and it is listed on the Nasdaq exchange.
ABSI stock is listed on the Nasdaq exchange.
15 analysts have analysed ABSI and the average price target is 9.31 USD. This implies a price increase of 197.36% is expected in the next year compared to the current price of 3.13. Check the ABSCI CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABSCI CORP (ABSI) has a market capitalization of 398.61M USD. This makes ABSI a Small Cap stock.
ABSCI CORP (ABSI) currently has 155 employees.
ABSCI CORP (ABSI) has a support level at 3.12 and a resistance level at 3.14. Check the full technical report for a detailed analysis of ABSI support and resistance levels.
The Revenue of ABSCI CORP (ABSI) is expected to grow by 89.99% in the next year. Check the estimates tab for more information on the ABSI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABSI does not pay a dividend.
ABSCI CORP (ABSI) will report earnings on 2025-05-13, before the market open.
ABSCI CORP (ABSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).
The outstanding short interest for ABSCI CORP (ABSI) is 19.08% of its float. Check the ownership tab for more information on the ABSI short interest.
ChartMill assigns a technical rating of 3 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI is a bad performer in the overall market: 81.69% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. The financial health of ABSI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 22.76% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -48.27% | ||
ROE | -57.56% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 83% to ABSI. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 2.39% and a revenue growth 89.99% for ABSI